• Every
  • Diagnosis
  • Counts

HiPath Pro

Group 4@1,5x
fda icon

FDA cleared for the HiPath IHC Family for HER2, ER, PR and Ki67, on the manual configuration

powered by geneasis
Asset 11@2x


Asset 12@2x


Asset 13@2x


“As an early adopter of the PD-L1 immunostain methodology, our group quickly recognized the inter and intra observer variability in scoring and interpretation of the stain, especially when there is non- uniform staining among tumor regions. We have been very pleased with the added confidence that HiPath Pro provides us in improving accuracy and precision of interpretation.”

( Dr. Lija Joseph, Lowell General Hospital )

HiPath Pro Highlights

Accurate, repeatable and standardized results

  • Cell based analysis of 1000’s of cells in relevant tumor regions
  • All nuclear and membrane staining
  • Wide range of tissue samples
  • Vendor neutral

Uncompromising Image Quality | Start & Walkaway Scanning

  • Virtual H&E and IHC slides
  • Tumor boards
  • Education & documentation
  • Archiving
  • Remote access

Standardization at the Click of a Button

Automatically segments tumor cells, counts signals and classifies cells based on amplification ratio

Centralized scanning with remote review and analysis

Start & walkaway scanning increases lab productivity and supports greater volumes

Central Portal and Database | Easily Integrates with Lab LIS

  • Efficient
  • Comprehensive
  • Eliminates human error

Lab Connectivity Anytime, Anywhere

Review, analyze and sign off case information from any location via a secured network




pdf icon

White paper

pdf icon